Gingiva-Derived Stem Cells for Wound Healing and Hypersensitivity

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for cutaneous wound healing and allergic contact dermatitis (ACD) are inadequate, with existing methods failing to effectively promote wound repair and manage inflammation, and there is a need for a more curative desensitizing tool targeting specific cellular targets in the complex immune responses involved in ACD.

Innovation Solution

The use of gingiva-derived mesenchymal stem cells (GMSCs) to reprogram macrophages into an anti-inflammatory M2 phenotype, promoting wound healing by suppressing inflammation and modulating immune cell functions through the COXs/PGE2 pathway, thereby enhancing skin wound repair and attenuating contact hypersensitivity.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If corticosteroid is applied topically for ACD treatment, then short-term symptom relief is achieved, but curative desensitization does not occur

Engineering Contradiction:

Improvecurative effectVSAvoidduration of symptom relief

Core Design Contradiction:

ReliabilityVSDuration of action of stationary object

Solution Approach 1:

The patent applies preliminary action by administering GMSCs before the elicitation phase of contact hypersensitivity. The cells are introduced during the sensitization phase or before challenge, allowing them to home to the site and modulate the immune response in advance, preventing rather than just treating the hypersensitivity reaction.

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The patent uses GMSCs as an intermediary mediator between the allergen and the immune system. These stem cells interact with multiple immune cell types (dendritic cells, T cells, macrophages) to modulate the hypersensitivity response, providing a curative effect that goes beyond simple symptom suppression.

Inventive Principle:

Principle #24Intermediary (Mediator)

2Productivity

If M1 macrophages are present in wound tissue, then inflammatory response is activated, but wound healing is delayed

Engineering Contradiction:

Improvewound healing speedVSAvoidinflammation level

Core Design Contradiction:

ProductivityVSObject-affected harmful factors

Solution Approach 1:

The patent applies parameter changes by shifting the macrophage phenotype from M1 (pro-inflammatory) to M2 (anti-inflammatory). This is achieved through GMSC-secreted factors that modify the activation state and functional parameters of macrophages, reducing inflammation while promoting wound healing.

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent converts the harmful prolonged inflammatory response into a beneficial healing process. By introducing GMSCs, the excessive M1-mediated inflammation is transformed into an M2-dominated environment that promotes tissue repair, angiogenesis, and remodeling, turning the harmful inflammatory phase into a healing phase.

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

3Productivity

If GMSCs are administered systemically, then wound healing is accelerated through M2 macrophage polarization, but the mechanism of action on immune cells needs clarification

Engineering Contradiction:

Improvewound closure rateVSAvoidmechanism understanding

Core Design Contradiction:

ProductivityVSDifficulty of detecting and measuring

Solution Approach 1:

The patent employs feedback mechanisms where GMSCs secreted factors (PGE2, IL-10, TGF-β) create a positive feedback loop that reinforces M2 macrophage polarization. The M2 macrophages in turn secrete factors that further promote wound healing and recruit additional GMSCs, amplifying the therapeutic effect.

Inventive Principle:

Principle #23Feedback

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

GMSCs accelerate wound closure, improve angiogenesis, and tissue remodeling by promoting M2 macrophage polarization, reducing inflammation, and suppressing contact hypersensitivity, demonstrating improved therapeutic outcomes for cutaneous wound healing and ACD.

Implementation Method 1

modulating immune cell functions through the COXs/PGE2 pathway

Methodology Applied

Scientific EffectCOXs/PGE2 pathway:

Data Source

PatentUS9682105B2Methods of promoting wound healing and attenuating contact hypersensitivity with gingiva-derived mesenchymal stem cells

Publication Date: 2017.06.20 UNIV OF SOUTHERN CALIFORNIA

AI summary

Disclosed are methods of polarizing macrophages to exhibit M2 phenotype, including introducing an effective amount of gingiva-derived mesenchymal stem cells to an environment comprising a population of macrophages such that the macrophages are in fluid communication with the gingiva-derived mesenchymal stem cells. Also disclosed are methods of promoting cutaneous wound healing including administering to a patient an effective amount of human gingiva-derived mesenchymal stem cells, thereby resulting in at least one of accelerated wound closure, rapid re-epithelialization, improved angiogenesis and improved tissue remodeling relative to untreated controls. Also disclosed are methods for attenuating contact hypersensitivity in a patient, the methods including administering to a patient an effective amount of human gingiva-derived mesenchymal stem cells at a time at least timeframe selected from the group consisting of before sensitization, after sensitization and before challenge and after challenge, thereby attenuating contact hypersensitivity.